Last reviewed · How we verify
fluticasone propionate + montelukast
Fluticasone propionate is a corticosteroid that reduces inflammation, while montelukast is a leukotriene receptor antagonist that prevents bronchospasm.
Fluticasone propionate is a corticosteroid that reduces inflammation, while montelukast is a leukotriene receptor antagonist that prevents bronchospasm. Used for Chronic asthma, Allergic rhinitis.
At a glance
| Generic name | fluticasone propionate + montelukast |
|---|---|
| Also known as | Flovent Diskus® + Singulair® |
| Sponsor | Milton S. Hershey Medical Center |
| Drug class | Corticosteroid + Leukotriene receptor antagonist |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Fluticasone propionate works by inhibiting the release of pro-inflammatory mediators, thereby reducing inflammation in the airways. Montelukast, on the other hand, blocks the action of leukotrienes, which are substances that cause bronchospasm and increase mucus production.
Approved indications
- Chronic asthma
- Allergic rhinitis
Common side effects
- Headache
- Cough
- Throat irritation
- Nausea
- Vomiting
- Dysphonia
- Oral candidiasis
- Hypersensitivity reactions
- Increased risk of pneumonia
- Osteoporosis
Key clinical trials
- BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) (PHASE2)
- ACTIV-6: COVID-19 Study of Repurposed Medications (PHASE3)
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone
- Asthma Research in Children and Adolescents
- The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study (PHASE4)
- Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation
- First Step With Singulair® Therapy (0476-323) (PHASE4)
- A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: